Newman Yeilding

7.3k total citations · 4 hit papers
34 papers, 5.7k citations indexed

About

Newman Yeilding is a scholar working on Immunology, Dermatology and Hematology. According to data from OpenAlex, Newman Yeilding has authored 34 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 14 papers in Dermatology and 8 papers in Hematology. Recurrent topics in Newman Yeilding's work include Psoriasis: Treatment and Pathogenesis (21 papers), Dermatology and Skin Diseases (14 papers) and Asthma and respiratory diseases (8 papers). Newman Yeilding is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (21 papers), Dermatology and Skin Diseases (14 papers) and Asthma and respiratory diseases (8 papers). Newman Yeilding collaborates with scholars based in United States, Canada and Germany. Newman Yeilding's co-authors include Cynthia Guzzo, Lisa T. Dooley, Shu Li, Kim Papp, Craig L. Leonardi, Alexa B. Kimball, Mark Lebwohl, Richard G. Langley, Kenneth B. Gordon and Philippe Szapary and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Newman Yeilding

34 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

2008 1.4k citations Craig L. Leonardi, Alexa B. Kimball et al. The Lancet profile →
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

2008 1.1k citations Kim Papp, Richard G. Langley et al. The Lancet profile →
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

2010 644 citations C.E.M. Griffiths, Bruce Strober et al. New England Journal of Medicine profile →
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis

2007 588 citations Gerald G. Krueger, Richard G. Langley et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Newman Yeilding

Since Specialization

Citations

This map shows the geographic impact of Newman Yeilding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Newman Yeilding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Newman Yeilding more than expected).

Fields of papers citing papers by Newman Yeilding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Newman Yeilding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Newman Yeilding. The network helps show where Newman Yeilding may publish in the future.

Co-authorship network of co-authors of Newman Yeilding

This figure shows the co-authorship network connecting the top 25 collaborators of Newman Yeilding. A scholar is included among the top collaborators of Newman Yeilding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Newman Yeilding. Newman Yeilding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study 2012 ·Journal of the European Academy of Dermatology and Venereology ·Alexa B. Kimball, Kim Papp, Yasmine Wasfi, Daphne Chan, Robert Bissonnette, Howard Sofen, Newman Yeilding, S. Li, Philippe Szapary, Kenneth B. Gordon, (unknown)	162
2	Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives – an update 2012 ·Annals of the New York Academy of Sciences ·Newman Yeilding, Philippe Szapary, Carrie Brodmerkel, Jacqueline Benson, Michael Plotnick, Honghui Zhou, Kavitha Goyal, Brad Schenkel, Jill Giles‐Komar, Mary Ann Mascelli, Cynthia Guzzo	22
3	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years 2012 ·British Journal of Dermatology ·Alexa B. Kimball, Ken Gordon, S. Fakharzadeh, Newman Yeilding, Philippe Szapary, Brad Schenkel, Cynthia Guzzo, (unknown), Kim Papp	110
4	Bounded outcome score modeling: application to treating psoriasis with ustekinumab 2011 ·Journal of Pharmacokinetics and Pharmacodynamics ·Chuanpu Hu, Newman Yeilding, Hugh M. Davis, Honghui Zhou	29
5	Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure–response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis 2011 ·Journal of Pharmacokinetics and Pharmacodynamics ·Chuanpu Hu, Philippe Szapary, Newman Yeilding, Honghui Zhou	34
6	Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives 2011 ·Annals of the New York Academy of Sciences ·Newman Yeilding, Philippe Szapary, Carrie Brodmerkel, Jacqueline Benson, Michael Plotnick, Honghui Zhou, Kavitha Goyal, Brad Schenkel, Jill Giles‐Komar, Mary Ann Mascelli, Cynthia Guzzo	60
7	Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials 2011 ·Journal of the American Academy of Dermatology ·Kenneth B. Gordon, Kim Papp, Richard G. Langley, Vincent Ho, Alexa B. Kimball, Cynthia Guzzo, Newman Yeilding, Philippe Szapary, Steven Fakharzadeh, Shu Li, (unknown), Kristian Reich	110
8	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials 2011 ·Journal of the American Academy of Dermatology ·Mark Lebwohl, Craig L. Leonardi, C.E.M. Griffiths, Jörg C. Prinz, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Shu Li, (unknown), Bruce Strober	82
9	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies 2011 ·British Journal of Dermatology ·Kristian Reich, Richard G. Langley, Mark Lebwohl, Philippe Szapary, Cynthia Guzzo, Newman Yeilding, (unknown), (unknown), C.E.M. Griffiths	96
10	Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis 2009 ·The Journal of Clinical Pharmacology ·Yaowei Zhu, Chuanpu Hu, Ming Lu, Sam Liao, Joseph C. Marini, (unknown), Newman Yeilding, Hugh M. Davis, Honghui Zhou	135
11	Population‐Based Exposure‐Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis 2009 ·The Journal of Clinical Pharmacology ·Honghui Zhou, Chuanpu Hu, Yaowei Zhu, Ming Lu, Sam Liao, Newman Yeilding, Hugh M. Davis	50
12	PSY42 USTEKINUMAB REDUCES ITCH, BODILY PAIN, AND FATIGUE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS 2009 ·Value in Health ·Mark Lebwohl, (unknown), (unknown), Brad Schenkel, Newman Yeilding, (unknown), (unknown)	2
13	Cardiovascular Disease and Risk Factors among Psoriasis Patients in Two US Healthcare Databases, 2001–2002 2008 ·Dermatology ·Alexa B. Kimball, Don Robinson, Ying Wu, Cynthia Guzzo, Newman Yeilding, Clark Paramore, Kathy Fraeman, M Bala	147
14	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) breakdown → 2008 ·The Lancet ·Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich	1067
15	A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis breakdown → 2007 ·New England Journal of Medicine ·Gerald G. Krueger, Richard G. Langley, Craig L. Leonardi, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Lisa T. Dooley, Mark Lebwohl	588
16	A multicenter, randomized, open study to evaluate the impact of an electronic data capture system on the care of patients with rheumatoid arthritis 2007 ·Current Medical Research and Opinion ·J. Eugene Huffstutter, (unknown), (unknown), (unknown), Jeffrey Lisse, Shelley Kasle, (unknown), David E. Yocum, (unknown), (unknown), (unknown), Newman Yeilding, (unknown)	7
17	Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study 2007 ·Annals of the Rheumatic Diseases ·D E Furst, Norman Gaylis, (unknown), Ewa Olech, David E. Yocum, J. Ritter, M H Weisman, (unknown), John V. Crues, Dinesh Khanna, Gisela Eckel, Newman Yeilding, (unknown), Sudha Visvanathan, (unknown), (unknown), Liziamma George, (unknown), (unknown), O. Troum	88
18	Tumor Vessel Development and Maturation Impose Limits on the Effectiveness of Anti-Vascular Therapy 2003 ·American Journal Of Pathology ·Michael S. Gee, (unknown), Sosina Makonnen, Michael D. Feldman, Newman Yeilding, William M. F. Lee	196
19	c-myc mRNA Is Down-regulated during Myogenic Differentiation by Accelerated Decay That Depends on Translation of Regulatory Coding Elements 1998 ·Journal of Biological Chemistry ·Newman Yeilding, (unknown), (unknown), William M. F. Lee	32
20	Analysis of two human monoclonal antibodies against melanoma 1992 ·International Journal of Cancer ·Newman Yeilding, (unknown), John M. Kirkwood	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact